The Metabolomics of Anaphylaxis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2012-03-31

Study Completion Date

2018-08-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Metabolomics is the study of metabolic pathways and the unique biochemical molecules which result from the regulatory response to physiological stressors, disease processes, or drug therapy. By measuring changes in metabolite concentrations, the range of biochemical effects and therapeutic intervention can be determined.

Aspirin exacerbated respiratory disease (AERD) is a chronic inflammatory disease characterized by chronic rhinosinusitis, nasal polyposis, asthma, and airway reactivity to aspirin and/or other nonsteroidal anti-inflammatory drugs (NSAIDs). This reaction to aspirin during challenge/desensitization is equivalent to an allergic drug reaction however we are able to evaluate these specific reactions in a controlled, clinical environment. This population of patients undergoing aspirin desensitization is ideal for studying metabolomics as serial blood sampling can be performed in patients before, during a reaction, and after aspirin desensitization, thereby allowing each patient to serve as his or her own biological control. The investigator hopes that this study of metabolomics will allow for better methods of identifying anaphylaxis in the future.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of Inflammatory Mediators in AERD

NCT02824523

Asthma, Aspirin-Induced

COMPLETED

Mechanisms of Acute Asthma Exacerbations Through Molecular Analysis of Airway Secretions and Tissues

NCT00603629

Asthma

COMPLETED

Role of Leukotrienes and Adenosine in Hyperpnea-induced Bronchospasm

NCT00710255

Asthma, Exercise Induced

COMPLETED

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban

NCT03326063

Nasal Polyps Asthma, Aspirin-Induced Aspirin-exacerbated Respiratory Disease +1 more

COMPLETED PHASE2

Metabolomic Analysis of Exhaled Breath Condensate in Asthmatics

NCT01439737

Asthma

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patients With AERD Undergoing Aspirin Desensitization

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aspirin desensitization

This group of patients has AERD (aspirin exacerbated respiratory disease) and is undergoing aspirin desensitization.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients ages 18-75 with a history of aspirin anaphylaxis or a history of hypersensitivity reaction to aspirin and referred for a clinically indicated outpatient or inpatient aspirin desensitization procedure for AERD.